Original Research
Post Hoc Analysis of Lung Function Improvement and Patient-Reported Outcomes with Revefenacin in Adults with Moderate-to-Very Severe COPD and Comorbid Anxiety or Depression

Abebaw M. Yohannes, PhD, MSc1,2 Anand S. Iyer, MD, MSPH2 Candice Clay, PhD3* Lauren Cochran, PharmD3 Xianyi Chen, MS3 David A. Lombardi, PhD3a Surya P. Bhatt, MD, MSPH2

1Department of Physical Therapy, School of Health Professions, University of Alabama at Birmingham, Birmingham, Alabama, United States

2Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, and Lung Health Center, University of Alabama at Birmingham, Birmingham, Alabama, United States

3Theravance Biopharma U.S., Inc., South San Francisco, California, United States

*At the time this study was conducted.

Address correspondence to:
Abebaw M. Yohannes, PhD, MSc
Department of Physical Therapy, School of Health Professions
Division of Pulmonary, Allergy and Critical Care Medicine
Lung Health Center
University of Alabama at Birmingham
Birmingham, AL,
Email: amyohann@uab.edu
Phone: (205) 934-3566

Running head: Patient-Reported Outcomes in Patients Taking Revefenacin

Keywords: Anxiety; depression; lung function; patient-reported outcomes; quality of life

Abbreviations: AE=adverse event; A=anxiety only; +A/+D=both anxiety and depression; −A/−D=neither anxiety nor depression; CAT=COPD Assessment Test; CI=confidence interval; COPD=chronic obstructive pulmonary disease; D=depression only; FEV1=forced expiratory volume in 1 second; LABA=long-acting beta agonist; LAMA=long-acting muscarinic antagonist; LS=least squares; MedDRA=Medical Dictionary for Regulatory Activities; MCID=minimum clinically important difference; PRO=patient-reported outcome; QOL=quality of life; SGRQ=St. George’s Respiratory Questionnaire; TEAE=treatment-emergent adverse event
Funding Support: Support for the development of this manuscript was funded by Theravance Biopharma U.S., Inc., San Francisco, California.

Date of Acceptance: January 4, 2024  |  Published Online Date: January 19, 2024

Citation: Yohannes AM, Iyer AS, Clay C, et al. Post hoc analysis of lung function improvement and patient-reported outcomes with revefenacin in adults with moderate-to-very severe COPD and comorbid anxiety or depression. *Chronic Obstr Pulm Dis*. 2024; Published online January 19, 2024. [https://doi.org/10.15326.jcopdf.2023.0465](https://doi.org/10.15326.jcopdf.2023.0465)
Abstract

Background: Revefenacin, a once-daily, nebulized, long-acting muscarinic antagonist approved in the US for the maintenance of chronic obstructive pulmonary disease (COPD), significantly improves lung function and quality of life versus placebo in patients with moderate-to-very severe COPD. Comorbid anxiety and/or depression may alter patients’ symptom perception and response to bronchodilators. The impact of revefenacin in patients with COPD with comorbid anxiety and/or depression has not been previously investigated.

Methods: This post hoc subgroup analysis examined data from two 12-week, randomized, Phase 3 trials in patients with moderate-to-very severe COPD with the following self-reported subgroups: anxiety only (A), depression only (D), anxiety and depression (+A/+D), and neither anxiety nor depression (−A/−D). We assessed change from baseline in trough forced expiratory volume in 1 second (FEV₁) at Day 85 and health status by the St. George’s Respiratory Questionnaire (SGRQ) and COPD Assessment Test (CAT).

Results: Of 812 patients, 90 (11%), 110 (14%), 141 (17%), and 471 (58%) had A, D, +A/+D, and −A/−D. Revefenacin versus placebo significantly improved from baseline trough FEV₁ at Day 85 across all subgroups as well as SGRQ and CAT scores in patients with A, +A/+D, and −A/−D. Revefenacin was well tolerated regardless of A/D status, with a minimal incidence of treatment-emergent antimuscarinic adverse events across subgroups.

Conclusions: In this analysis, revefenacin versus placebo significantly improved health outcomes in patients with moderate-to-very severe COPD with A, +A/+D, and −A/−D, but not in patients with D. The safety profile of revefenacin was not affected by comorbid anxiety/depression status.
Introduction

Chronic obstructive pulmonary disease (COPD) is characterized by chronic inflammation and progressive lung function decline that affects over 392 million people worldwide.\(^1,2\) COPD is associated with impaired quality of life (QOL), reduced social interactions, high healthcare utilization, and caregiver burden, especially in the presence of comorbidities.\(^3\) Over 60% of patients with COPD exhibit two or more chronic comorbid conditions.\(^4-6\) Of these conditions, anxiety and depression are common, and the prevalence of clinically relevant anxiety and depression symptoms in patients with COPD is estimated to range for both from 22% to 48%.\(^7-9\) Underlying anxiety and/or depression symptoms are often underreported, underdiagnosed and undertreated, and can predict severe respiratory exacerbations and severity of COPD and asthma,\(^10-12\) which can result in impaired QOL and increased healthcare utilization compared to patients without these symptoms.

Untreated anxiety and/or depression compounds patients’ COPD by worsening several outcomes, including increased physical disability, elevated dyspnea, early dropout from pulmonary rehabilitation programs, increased exacerbation risk, increased episodes of hospital readmissions, and poor adherence to COPD therapies.\(^13-17\) Given that sensory information from breathing activates cortical regions of the brain to create the perception of dyspnea, it is apparent that there is a bidirectional relationship between emotion and dyspnea, with heightened anxiety and/or depression perhaps leading to increases in ventilation and worsening of dyspnea.\(^18,19\) Furthermore, alleviating dyspnea through bronchodilators may help to reduce the baseline for dyspnea perception and the effect of anxiety and/or depression on elevating dyspnea symptoms. In addition, treatment of underlying psychiatric disorders in patients with COPD improves pulmonary status and other respiratory outcomes.\(^20,21\)
Bronchodilators are central to the management of COPD symptoms. However, a recent observational study examining the level of adherence to inhaler therapy in patients with COPD in a primary care setting found that ~75% of patients were non-adherent. In another study the presence of dyspnea in patients with COPD was significantly associated with depression symptoms and low treatment adherence to COPD medications was correlated with depression scores and negative long-term outcomes. To date, factors that contribute to low adherence to inhaler therapy in patients with COPD are poorly understood. The complex multifactorial problem of non-adherence includes physical disability (eg, dexterity problems), psychological (eg, elevated anxiety or depression) and/or cognitive impairment, costs related to medications, and difficulty managing different inhaler devices. Together with poor inhaler adherence, individuals with comorbid anxiety and/or depression may also have altered symptom perception and may therefore respond differently to bronchodilators; however, this has not been well studied. Adherence to medication, therefore, should be a key factor when treating the respiratory symptoms of patients with COPD who may also have comorbid anxiety and/or depression. This is exemplified among adults with asthma where major depression was associated with a decrease in bronchodilator response and a worsening of respiratory outcomes.

Revefenacin is a once-daily nebulized, long-acting muscarinic antagonist (LAMA) approved in the US for the maintenance treatment of COPD. In Phase 3 clinical trials, revefenacin demonstrated statistically and clinically significant improvements in lung function and QOL versus placebo in patients with moderate-to-very severe COPD. Revefenacin was also well tolerated in these trials, with high medication adherence rates (more than 90% of patients had adherence rates of 80% or more). Here we examine the potential benefits of revefenacin, specifically in the management of patients with COPD who also have self-reported...
comorbid anxiety and/or depression, by conducting an exploratory post hoc analysis of pooled data from two 12-week Phase 3 trials. Utilizing these pooled data, we evaluated lung function via trough forced expiratory volume in 1 second (FEV₁) at Day 85 and COPD-specific health-related patient-reported outcomes (PROs) in patients with moderate-to-very severe COPD with comorbid anxiety and/or depression. Due to the once-daily dosing regimen, ease of administration, and previously demonstrated high adherence rates, we hypothesized that the impact of revefenacin on lung function and PROs would be consistent across the anxiety/depression subgroups of patients with COPD.

Methods

Trial Design and Patients

For this exploratory post hoc analysis, data were pooled from two 12-week, replicate, randomized, double-blind, placebo-controlled Phase 3 trials (0126 [NCT02459080] and 0127 [NCT02512510]) in patients with moderate-to-very severe COPD as described previously. The protocols for these Phase 3 trials were approved by the institutional review boards at participating sites and written consent was obtained from patients before trial procedures were initiated.

Briefly, the trials enrolled patients (aged ≥40 years) with spirometric confirmation of COPD, post-ipratropium FEV₁/forced vital capacity ratio of 0.7, post-ipratropium FEV₁ <80% of predicted normal, and smoking history of ≥10 pack-years. Key exclusion criteria included history of myocardial infarction or unstable angina in the previous 6 months, unstable or life-threatening cardiac arrhythmia requiring intervention in the previous 3 months, New York Heart Association Class IV heart failure prior to trial initiation, or abnormal and clinically significant 12-lead
electrocardiogram at trial entry. Patients were randomized 1:1:1 to receive revefenacin 88 µg, revefenacin 175 µg, or placebo once daily in the morning administered via the PARI LC Sprint® jet nebulizer (Pari Respiratory Equipment, Inc., Starnberg, Germany) for 12 weeks. Only patients who received revefenacin 175 µg (the US Food and Drug Administration approved dose) or placebo were included in this exploratory analysis (trial overview; Figure 1). Concomitant long-acting beta agonist (LABA)–containing therapy (with or without inhaled corticosteroids) was used in 37% of the trial population.

Patients self-identified psychiatric disorders during the data collection of their medical history. Medical history terms were mapped according to the Medical Dictionary for Regulatory Activities (MedDRA) version 18.1. Psychiatric disorders were then categorized as anxiety and/or depression by expert (AMY, ASI, SPB) adjudication and consensus was reached by discussion. Patients were grouped as having anxiety only (A), depression only (D), both anxiety and depression (+A/+D), or neither anxiety nor depression (−A/−D).

Assessments and Endpoints

Efficacy outcomes were evaluated in each of the 4 patient subgroups. The change from baseline in trough FEV₁ (defined as the mean of the 23.25- and 23.75-hour spirometry assessments following the 84th dose) at Day 85 was evaluated. Following the final dose at Day 85, the percentage of patient responders, defined as having a ≥100-mL increase in post-bronchodilator FEV₁ within 2 hours of dose administration, was quantified.

This subanalysis assessed patient responses on the St. George’s Respiratory Questionnaire (SGRQ)31 and the COPD Assessment Test (CAT).32 Endpoints were change from baseline in SGRQ and CAT scores at Day 85. Responder analysis measured the percentage of
patients with a minimum clinically important difference (MCID) in SGRQ (≥4-unit decrease from baseline) and/or CAT (≥2-unit decrease from baseline) scores at Day 85.

Safety assessments included treatment-emergent adverse events (TEAEs) and adverse events (AEs) commonly associated with antimuscarinic agents, including dry eye, dry mouth, dysuria, and constipation. The incidence of TEAEs and antimuscarinic AEs was compared across subgroups.

Statistical Analysis

Responses were assessed in the intention-to-treat population, defined as all patients who were randomized, received ≥1 dose of treatment, and had ≥1 postbaseline spirometry assessment. Least-squares (LS) mean changes from baseline in trough FEV1 at Day 85 and LS mean treatment differences between revefenacin 175 μg and placebo were estimated using a mixed model for repeated measures. LS proportions of responders at Day 85 were compared using a repeated-measures logistic regression model. The efficacy outcomes were adjusted for clinically significant variables that affect FEV1. LS mean changes from baseline in SGRQ and CAT scores at Day 85 and LS mean differences between revefenacin and placebo were estimated using a mixed model for repeated measures. The model included fixed effect class terms for treatment group, smoking status, reversibility status, concomitant LABA use at baseline, sex, and age at baseline. Odds ratio estimates and differences between revefenacin and placebo in the PRO responders were compared using a repeated-measures logistic regression model using similar covariates as above. Significance was set at $P < 0.05$.

Results
Sociodemographic Characteristics

Across the two Phase 3 trials, 1229 patients were randomized, of which a total of 266 discontinued the trial treatment period. For this exploratory post hoc analysis, of the 812 patients who were randomized to either revefenacin 175 μg or placebo, 90 (11%) had A, 110 (14%) had D, 141 (17%) had +A/+D, and 471 (58%) had −A/−D based on self-reporting (Table 1). The mean age was 59 to 66 years across subgroups. The mean baseline post-ipratropium percent predicted FEV1 was 53% to 57%. A greater percentage of patients with A (68%), D (55%), or +A/+D (66%) were women compared with −A/−D (42%). A larger percentage of patients with +A/+D (64%) were smoking at baseline than those with A (53%), D (44%), or −A/−D (43%).

Lung Function

Revefenacin produced significant improvements from baseline versus placebo in trough FEV1 at Day 85 across all subgroups. The placebo-adjusted LS mean change (95% confidence interval [CI]; P-value) was 152 mL (55 to 250; <0.002) in patients with A, 111 mL (19 to 204; 0.02) with D, 150 mL (69 to 231; <0.001) with +A/+D, and 159 mL (116 to 202; <0.001) with −A/−D (Figure 2).

More patients who received revefenacin had a clinically relevant improvement of ≥100 mL from baseline in FEV1 versus placebo across all subgroups (Figure 3). The difference between revefenacin and placebo was not statically significant in patients with D, potentially due to limited sample sizes.

St. George’s Respiratory Questionnaire Score
**Figure 4** shows that compared with placebo, revefenacin significantly improved total SGRQ scores (placebo-adjusted LS mean change [95% CI; \(P\)-value]) in patients with A (−8.2 [−13.2 to −3.1; 0.002]), +A/+D (−5.6 [−9.6 to −1.5; 0.007]), and −A/−D (−2.4 [−4.7 to −0.2; 0.03]). However, improvements in SGRQ scores were not significantly different for those with D (−0.9 [−5.5 to 3.7; 0.70]). SGRQ scores meeting the responder criterion for revefenacin and placebo were observed in 51% and 32% of patients with A, 36% and 33% with D, 60% and 40% with +A/+D, and 45% and 36% with −A/−D, respectively.

**COPD Assessment Test Score**

CAT scores (placebo-adjusted LS mean change [95% CI; \(P\)-value]) improved in patients with A (−4.1 [−6.5 to −1.8; <0.001]), +A/+D (−2.9 [−4.8 to −1.0; 0.003]), and −A/−D (−1.5 [−2.6 to −0.5; 0.004]). However, CAT scores were not significantly different for those with D (0.6 [−1.6 to 2.8; 0.61]). CAT scores meeting the responder criterion for revefenacin and placebo were observed in 61% and 29% of patients with A, 38% and 53% with D, 52% and 36% with +A/+D, and 49% and 33% with −A/−D, respectively, as shown in **Figure 4**.

**Safety and Adverse Events**

Across the two Phase 3 trials, 180/812 (22.2%) patients from the randomized and treated analysis set discontinued the trial treatment period (72/395 [18.2%] revefenacin 175 µg and 108/417 [25.9%] placebo; discontinuation rates for the A/D subgroups were not recorded). In this exploratory post hoc analysis, AEs were reported in 56% of patients with A, 56% with D, 51% with +A/+D, and 48% with −A/−D. Revefenacin was generally well tolerated regardless of comorbid anxiety or depression status, with similar percentages of patients reporting TEAEs.
across subgroups. The incidence of treatment-emergent antimuscarinic AEs was minimal across all subgroups (Table 2).

**Discussion**

We examined the effects of revefenacin (a LAMA administered once daily for the maintenance treatment of patients with COPD) on lung function and QOL improvements in patients with COPD who also had self-reported anxiety and/or depression in an exploratory post hoc subgroup analysis from 2 randomized controlled trials. Compared with placebo, revefenacin achieved clinically significant improvements in lung function in the subgroups of anxiety only (A), depression only (D), and anxiety and depression (+A/+D), with a treatment benefit similar to those without these comorbidities (−A/−D). Importantly, revefenacin showed clinically significant improvement in SGRQ and CAT scores in the A, +A/+D, and −A/−D subgroups when compared with placebo, but not in patients with D.

One in 6 patients self-reported comorbid +A/+D at baseline in these Phase 3 clinical trials. These findings are similar to another exploratory analysis of subcategorized +A/+D patients with moderate-to-very severe COPD receiving nebulized glycopyrrolate 25 µg administered twice daily, which resulted in numerical improvements in FEV₁ and SGRQ total scores and responder rates irrespective of baseline A/D status. One difference between these treatments is that revefenacin administration is once daily, which reduces the treatment burden for patients with COPD versus twice-daily administration of glycopyrrolate. The prevalence of combined anxiety and depression in patients with COPD in these revefenacin phase 3 trials and the glycopyrrolate trials is approximately half the prevalence reported in an outpatient pulmonary rehabilitation program using clinically validated anxiety and depression outcome measures.
This variation in anxiety and depression prevalence might be due to the self-reporting of +A/+D in the present revefenacin and prior glycopyrrolate studies, reflecting a patient’s reluctance or lack of comprehension regarding anxiety and depression unless specifically probed by healthcare professionals using validated anxiety and depression scales.34

Revefenacin showed significant improvement in trough FEV₁ at Day 85 compared with placebo independent of anxiety and depression status (similar results were also demonstrated with glycopyrrolate administration).33 Although the clinical significance of lung function improvement observed (change from baseline in trough FEV₁) in all subgroups of patients who received revefenacin versus placebo is unclear, these results contrast from the aforementioned glycopyrrolate study in which significant lung function improvements were only observed in the −A/−D group.33 The differences observed between the two studies may be related to trial design and the patient population.

The change in total SGRQ and CAT scores from baseline at Day 85 reached an MCID in only the A and +A/+D groups compared with placebo. Though statistically significant, improvements did not reach the MCID in the −A/−D group compared with placebo. This may be due to the differences in baseline SGRQ and CAT scores, which were higher in the A and +A/+D subgroups compared with the D and −A/−D groups. Caution is needed in the interpretation of SGRQ and CAT scores as studies generally require more than 12 weeks to show clinically meaningful differences with treatment, even when sufficiently powered. In addition, depression is linked to noncompliance with medical treatment.35 Although we did not evaluate adherence or compliance specifically in any of these subgroups due to the post hoc nature of this analysis, a combination of these factors could have contributed to the lack of improvement in SGRQ and CAT scores. Of note, in the two Phase 3 trials of revefenacin, medication adherence
rates were high (more than 90% of patients had adherence rates of 80% or more). These high adherence rates to revefenacin are notable given the high medication burden, regimen complexity for patients with COPD, and managing symptom load of comorbidities.

The safety profile of revefenacin was similar to placebo in patients with COPD with and without comorbid anxiety and/or depression. This is consistent with previously reported data from the two Phase 3 trials of revefenacin.

Revefenacin is a tertiary amine distinct from other LAMAs, such as glycopyrrolate and tiotropium, which are quaternary ammoniums. The unique structure and long dissociation half-life from the M3 receptor allows revefenacin to produce sustained (long duration of action) bronchodilation, with fewer antimuscarinic side effects. The results of our exploratory post hoc analysis describe the efficacy and safety of revefenacin in a specific population of patients with COPD (those with comorbid anxiety and/or depression). A previous post hoc subgroup analysis of these same Phase 3 trials investigated the efficacy of revefenacin in patients with markers of more severe COPD and comorbidity risk factors (such as history of cardiovascular disease, diabetes, and cognitive/mental impairments). In both post hoc analyses, LS mean differences in Day 85 trough FEV₁ favored patients who received revefenacin versus placebo across subgroups. This benefit of revefenacin was also observed when examining SGRQ in all subgroups, with the exception of patients with depression alone and patients over the age of 75. Overall, the significant improvement in lung function combined with the tolerability afforded by revefenacin in this exploratory post hoc analysis examining comorbid anxiety and/or depression subgroups provide useful information to healthcare professionals when assessing and treating these specific subpopulations of patients with COPD.
Strengths of this post hoc analysis include the large sample size drawn from two pivotal Phase 3 trials of revefenacin in comparison with placebo on a background of standard of care, including 37% of patients using LABA (with or without inhaled corticosteroids) therapy. In addition, and in contrast to the previously mentioned glycopyrrolate study, an expert independent blinded panel was utilized for confirmation of self-reported anxiety and depression symptoms from medical notes. This exploratory post hoc analysis has several limitations. First, this was not a prespecified subgroup analysis and information on patient use of antidepressants or antianxiety medications was not gathered in a systematic way; therefore, these results should be considered hypothesis-generating. Although an independent expert blinded panel confirmed patient anxiety and/or depression status (comorbidities were first identified by patient self-reports and were matched with the MedDRA preferred terms), the use of validated anxiety and depression scales may have resulted in the detection of more individuals with anxiety and/or depression in this post-coronavirus 2019 era given the complex mental health needs of patients with COPD, as well as other chronic diseases. Additionally, findings may not be generalizable to patients with COPD with mild respiratory impairments given the moderate-to-severe COPD population recruited to these trials. Finally, caution is needed regarding the interpretation of these findings as there was no examination of treatment adherence or discontinuation rates in this post hoc analysis.

Conclusions

In patients with moderate-to-very severe COPD, revefenacin produced significant improvements in trough FEV₁ at Day 85 compared with placebo, independent of anxiety and/or depression status. In addition, revefenacin improved SGRQ and CAT scores in patients with
COPD who also reported comorbid A, +A/+D, and –A–D in this exploratory post hoc analysis. QOL improvements in the D subgroup were not statistically significant. Along with the high levels of adherence demonstrated in the parent Phase 3 trials, combined with the simplicity of administration, the findings of this subanalysis support the use of revefenacin in patients with COPD who have comorbid conditions such as anxiety and/or depression.
Acknowledgements:

All authors conform to the ICMJE guidelines for authorship and substantially participated in the creation of the submitted work.

Author Contributions:

All authors have significantly contributed to and approved the final version of the manuscript and take responsibility for the integrity of the work.

**Abebaw M. Yohannes** contributed to methodology, data analysis, writing – original draft, and writing – reviewing/editing the manuscript.

**Anand S. Iyer** contributed to conceptualization and writing – reviewing/editing the manuscript.

**Candice Clay** contributed to conceptualization, data curation, formal analysis, writing – original draft, and writing – reviewing/editing the manuscript.

**Lauren Cochran** contributed to conceptualization, data curation, formal analysis, project administration, and writing – reviewing/editing the manuscript.

**Xianyi Chen** contributed to validation, visualization, and writing – reviewing/editing the manuscript.

**David A. Lombardi** contributed to conceptualization, formal analysis, and writing – reviewing/editing the manuscript.

**Surya P. Bhatt** contributed to investigation and writing – reviewing/editing the manuscript.
Data Sharing Statement:

Theravance Biopharma (and its affiliates) will not be sharing individual deidentified patient data or other relevant study data documents at this time.
Declarations of Interest:

Abebaw M. Yohannes reports receiving support for attending meetings and/or travel from Theravance Biopharma.

Anand S. Iyer reports receiving grants from the NIH National Institute on Aging, consulting fees from AstraZeneca, and speaking fees from Ascension.

Candice Clay reports being an employee of Verona Pharma and a former employee and stock owner of Theravance Biopharma at the time of the study.

Lauren Cochran reports being an employee and stock owner of Theravance Biopharma.

Xianyi Chen reports being an employee of Theravance Biopharma.

David A. Lombardi reports being a contract employee of Theravance Biopharma at the time of his contribution as the project statistician.

Surya P. Bhatt reports receiving grants from the NIH, consulting fees from Sanofi, Regeneron, and Boehringer Ingelheim, and participation in a data safety monitoring board for the NIH.

Editorial support was provided by Gregory Suess, PhD, CMPP, of AlphaBioCom, a Red Nucleus company, and was funded by Theravance Biopharma US, Inc., San Francisco, CA, USA.
References


doi:10.1016/j.rmed.2022.106850


11. Stubbs MA, Clark VL, Gibson PG, Yorke J, McDonald VM. Associations of symptoms of anxiety and depression with health-status, asthma control, dyspnoea, dysfunction breathing and obesity in people with severe asthma. *Respir Res*. 2022;23:341.


doi:10.3949/ccjm.85.s1.03


15. Yohannes AM, Casaburi R, Dryden S, Hanania NA. Predictors of premature discontinuation and prevalence of dropouts from a pulmonary rehabilitation program in
doi:10.1016/j.rmed.2022.106742

doi:10.1378/chest.15-0449


doi:10.1164/ajrccm.159.1.ats898


2023;17:17534666231206249. doi:10.1177/17534666231206249


Table 1. Baseline Patient Demographics and Clinical Characteristics From Pooled Trials (0126 and 0127)

<table>
<thead>
<tr>
<th></th>
<th>A n = 90</th>
<th>D n = 110</th>
<th>+A/+D n = 141</th>
<th>−A/−D n = 471</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Revefenacin</td>
<td>Placebo</td>
<td>Revefenacin</td>
<td>Placebo</td>
</tr>
<tr>
<td>Age, years, mean (SD)</td>
<td>63.5 (8.2)</td>
<td>61.2 (9.8)</td>
<td>65.5 (9.1)</td>
<td>66.4 (8.4)</td>
</tr>
<tr>
<td>Sex, female, n (%)</td>
<td>32 (65.3)</td>
<td>29 (70.7)</td>
<td>33 (54.1)</td>
<td>27 (55.1)</td>
</tr>
<tr>
<td>Race, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>46 (93.9)</td>
<td>40 (97.6)</td>
<td>54 (88.5)</td>
<td>42 (85.7)</td>
</tr>
<tr>
<td>Black or African</td>
<td>3 (6.1)</td>
<td>1 (2.4)</td>
<td>6 (12.2)</td>
<td>6 (12.2)</td>
</tr>
<tr>
<td>American</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline BMI, kg/m², mean (SD)</td>
<td>29.9 (7.1)</td>
<td>27.0 (5.5)</td>
<td>30.2 (6.7)</td>
<td>30.9 (6.7)</td>
</tr>
<tr>
<td>Current smoker, n (%)</td>
<td>22 (44.9)</td>
<td>26 (63.4)</td>
<td>31 (50.8)</td>
<td>17 (34.7)</td>
</tr>
<tr>
<td>Concomitant LABA or LABA/ICS use, n (%)</td>
<td>17 (34.7)</td>
<td>9 (22.0)</td>
<td>21 (34.4)</td>
<td>20 (40.8)</td>
</tr>
<tr>
<td>Baseline post-ipratropium percent predicted FEV₁, mean (SD)</td>
<td>53.7 (15.3)</td>
<td>56.2 (13.5)</td>
<td>54.3 (12.7)</td>
<td>56.6 (12.6)</td>
</tr>
<tr>
<td>Baseline SGRQ total score, mean (SD)</td>
<td>51.9 (16.5)</td>
<td>54.9 (18.0)</td>
<td>48.7 (18.3)</td>
<td>48.2 (14.8)</td>
</tr>
<tr>
<td>-------------------------------------</td>
<td>------------</td>
<td>------------</td>
<td>------------</td>
<td>------------</td>
</tr>
<tr>
<td>Baseline CAT score, mean (SD)</td>
<td>21.5 (7.6)</td>
<td>22.6 (8.0)</td>
<td>19.8 (7.8)</td>
<td>19.2 (7.5)</td>
</tr>
</tbody>
</table>

Percentages were derived using the number of patients receiving each treatment (revefenacin or placebo) within each subgroup (A, D, +A/+D, and −A/−D) as the denominator.

+A/+D, anxiety and depression; −A/−D, neither anxiety nor depression; A, anxiety only; BMI, body mass index; CAT, COPD Assessment Test; COPD, chronic obstructive pulmonary disease; D, depression only; FEV₁, forced expiratory volume in 1 second; ICS, inhaled corticosteroid; LABA, long-acting beta agonist; SD, standard deviation; SGRQ, St. George’s Respiratory Questionnaire.
Table 2. Pooled Treatment-Emergent Adverse Events (≥5% Incidence)

<table>
<thead>
<tr>
<th></th>
<th>A  n = 90</th>
<th></th>
<th>D  n = 110</th>
<th></th>
<th>+A/+D  n = 141</th>
<th></th>
<th>−A−D  n = 471</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Revefenacin</td>
<td>Placebo</td>
<td>Revefenacin</td>
<td>Placebo</td>
<td>Revefenacin</td>
<td>Placebo</td>
<td>Revefenacin</td>
<td>Placebo</td>
</tr>
<tr>
<td></td>
<td>n = 49</td>
<td>n = 41</td>
<td>n = 61</td>
<td>n = 49</td>
<td>n = 66</td>
<td>n = 75</td>
<td>n = 219</td>
<td>n = 252</td>
</tr>
<tr>
<td>TEAEs, n (%)</td>
<td>27 (55.1)</td>
<td>23 (56.1)</td>
<td>35 (57.4)</td>
<td>27 (55.1)</td>
<td>34 (51.5)</td>
<td>38 (50.7)</td>
<td>107 (48.9)</td>
<td>118 (46.8)</td>
</tr>
<tr>
<td>COPD</td>
<td>4 (8.2)</td>
<td>4 (9.8)</td>
<td>5 (8.2)</td>
<td>10 (20.4)</td>
<td>8 (12.1)</td>
<td>8 (10.7)</td>
<td>25 (11.4)</td>
<td>26 (10.3)</td>
</tr>
<tr>
<td>Cough</td>
<td>1 (2.0)</td>
<td>1 (2.4)</td>
<td>5 (8.2)</td>
<td>4 (8.2)</td>
<td>1 (1.5)</td>
<td>5 (6.7)</td>
<td>10 (4.6)</td>
<td>7 (2.8)</td>
</tr>
<tr>
<td>Dyspnea</td>
<td>1 (2.0)</td>
<td>1 (2.4)</td>
<td>2 (3.3)</td>
<td>2 (4.1)</td>
<td>1 (1.5)</td>
<td>7 (9.3)</td>
<td>8 (3.7)</td>
<td>13 (5.2)</td>
</tr>
<tr>
<td>Headache</td>
<td>2 (4.1)</td>
<td>2 (4.9)</td>
<td>5 (8.2)</td>
<td>2 (4.1)</td>
<td>2 (3.0)</td>
<td>2 (2.7)</td>
<td>7 (3.2)</td>
<td>5 (2.0)</td>
</tr>
<tr>
<td>Nasopharyngitis</td>
<td>0 (0)</td>
<td>1 (2.4)</td>
<td>1 (1.6)</td>
<td>2 (4.1)</td>
<td>2 (3.0)</td>
<td>0 (0)</td>
<td>12 (5.5)</td>
<td>6 (2.4)</td>
</tr>
<tr>
<td>Oropharyngeal pain</td>
<td>1 (2.0)</td>
<td>0 (0)</td>
<td>2 (3.3)</td>
<td>0 (0)</td>
<td>1 (1.5)</td>
<td>4 (5.3)</td>
<td>2 (0.9)</td>
<td>2 (0.8)</td>
</tr>
</tbody>
</table>

Percentages were derived using the number of patients receiving each treatment (revefenacin or placebo) within each subgroup (A, D, +A/+D, and −A−D) as the denominator.

+A/+D, anxiety and depression; −A−D, neither anxiety nor depression; A, anxiety only; COPD, chronic obstructive pulmonary disease; D, depression only; TEAE, treatment-emergent adverse event.
Figure 1. Replicate Phase 3 Program Overview


\(^a\)500 mcg. \(^b\)Patients randomized to revefenacin 175 µg (only 175 µg is approved for the maintenance treatment of patients with COPD) or placebo were included in the present analysis.

AE, adverse event; CAT, COPD Assessment Test; COPD, chronic obstructive pulmonary disease; SGRQ, St. George’s Respiratory Questionnaire.
Figure 2. Change From Baseline in Trough FEV₁ at Day 85 by Comorbid Anxiety and Depression Status

CI, confidence interval; FEV₁, forced expiratory volume in 1 second; LS, least squares.
**Figure 3.** Patients With a $\geq 100$-mL Increase From Baseline in Trough FEV$_1$ at Day 85

$n/N =$ male/female.

CI, confidence interval; FEV$_1$, forced expiratory volume in 1 second.
**Figure 4.** Patient-Reported Outcomes for the SGRQ and CAT Response Scores

+A/+D, anxiety and depression; −A/−D, neither anxiety nor depression; A, anxiety only;

CAT, COPD Assessment Test; CI, confidence interval; COPD, chronic obstructive pulmonary disease; D, depression only; LS, least squares; SGRQ, St. George’s Respiratory Questionnaire.